Tag: cardiovascular

1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease. 2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Polypills combining...

1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...

1. Combined use of intracoronary near-infrared spectroscopy (NIRS) and intravascular ultrasound were effective at detecting untreated intracoronary lesions at high risk of major adverse cardiac event (MACE). 2. Highly lipidic lesions and large plaque burden were found to be independent predictors of non-culprit lesion-related MACEs. Evidence Rating Level: 2 (Good) Study Rundown:...

1. Stopping renin-angiotensin system inhibition in patients with advanced chronic kidney disease was associated with higher risk of mortality, major cardiovascular events, and lower risk of kidney replacement therapy. Evidence Rating Level: 2 (Good) Studies have shown that renin-angiotensin system inhibitors (RASi) are effective in delaying chronic kidney disease (CKD) progression. Angiotensin-converting enzyme...

1. Positive fecal immunochemical test (FIT) results were associated with increased incidences of ischemic stroke, myocardial infarction, and all-cause mortality. Evidence Rating Level: 2 (Good) While fecal immunochemical tests (FIT) is a commonly used and effective screening tool for colorectal cancer (CRC), their clinical use in detecting other diseases is poorly known....

1. The rate of clinical events and all-cause mortality was similar in patients with drug-coated balloon therapy compared to those with drug-eluting stent therapy. 2. Treatment with drug-coated balloons yielded non-significantly decreased rates of major bleeding and probable or definite stent thrombosis.  Evidence Rating Level: 1 (Excellent) Study Rundown: Drug-coated balloons (DCBs)...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...

1. Patients who received rivaroxaban had a statistically significantly longer mean time until occurrence of a major clinical event compared to those who received warfarin. 2. The incidence of secondary-outcome events such as transient ischemic attack (TIA), valve thrombosis, and non-CNS embolism were similar between groups. Evidence Rating Level: 1 (Excellent) Study...

1. A 6% risk reduction for developing hypertension was associated with a 1-point improvement in Life’s Simple 7 score, a metric for cardiovascular health. Evidence Rating Level: 2 (Good) Hypertension is a condition that affects roughly half of the adult US population, and is a known risk factor for cardiovascular disease...